Monopar Therapeutics 8-K

What Happened

• Monopar Therapeutics (MNPR) filed a Form 8-K on March 27, 2026 to disclose its results of operations and financial condition for the quarter and full year ended December 31, 2025. The company attached a press release dated March 27, 2026 as Exhibit 99.1 that reports those financial results. The filing also includes the cover page interactive XBRL data file.

Key Details

• Filing date: March 27, 2026 (Form 8-K).
• Reporting period: Fourth quarter and full year ended December 31, 2025.
• Item reported: 2.02 (Results of Operations and Financial Condition); press release attached as Exhibit 99.1.
• The 8-K itself attaches the press release with the announced results; no additional financial statements or management discussion beyond the press release are included in this Form 8-K.

Why It Matters

• This filing signals Monopar has published its quarterly and annual earnings information—critical for investors tracking revenue, net income/loss, cash position and operating trends. Retail investors should read the attached press release (Exhibit 99.1) for the specific figures and any commentary on guidance or cash runway, and watch for any follow-up filings (e.g., Form 10-Q/10-K or investor call) that provide more detail.